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Abstract Cancer treatment is a fragmented and varied
process, as ‘‘cancer’’ is really hundreds of different dis-
eases. The ‘‘hallmarks of cancer’’ proposed by Hanahan
and Weinberg (Cell 100(1):57–70, 2000) are a framework
for viewing cancer within a common set of underlying
principles—ten properties that are common to almost all
cancers, allowing them to grow uncontrollably and ravage
the body. We used a cellular automaton model of tumour
growth paired with lattice Boltzmann methods modelling
oxygen flow to simulate combination drugs targeted at
knocking out pairs of hallmarks. We found that knocking
out some pairs of cancer-enabling hallmarks did not pre-
vent tumour formation, while other pairs significantly
prevent tumour growth (p ¼ 0:0004 using Wilcoxon
signed-rank adjusted with the Bonferroni correction for
multiple comparisons). This is not what would be expected
from models of knocking out the hallmarks individually, as
many pairs did not have an additive effect but had either no
statistically significant effect or a multiplicative one. We
propose that targeting certain pairs of cancer hallmarks,
specifically cancers ability to induce blood vessel devel-
opment paired with another cancer hallmark, could prove
an effective cancer treatment option.
Keywords Cancer modelling  Cellular automata 
Cancer hallmarks  Lattice Boltzmann  Binary fluid
1 Introduction
As of 2004, cancer was the leading cause of death in the
developed world and the second leading cause of death in
the developing world (World Health Organization 2008),
with about 12.7 million cases of cancer in 2008 alone
(Ferlay et al. 2008). While much time, money and research
are dedicated to cancer the statistics are grim, with little to
no progress in some cancers—for example, there has been
no significant improvement in survival rates of pancreatic
cancer in two decades (Sener et al. 1999). We have created
a highly abstract cellular automaton model of early cancer
growth and a lattice Boltzmann model of oxygen flow in
blood that investigates the impact of knocking out pairs of
‘‘cancer hallmarks’’.
While the traditional reductionist approach to studying
cancer has been successful in targeting some forms of the
disease, new approaches are needed that can study cancer
across scales (Rejniak and Anderson 2012). In silico
modelling of cancer is an nascent approach to attacking this
problem. Multiscale modelling is a powerful tool for cancer
simulation as it allows modelling at the cellular level, and
at the fluid level in order to accurately model oxygen flow.
Since oxygen availability is critical for cancer progression,
modelling both scales provides a more realistic model.
Many cancer models currently exist, including: Anderson
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et al.’s multiscale mathematical model of 2-dimensional
tumour growth (Anderson et al. 2006); Lloyd et al.’s
computational framework for solid tumour growth, which
comprised models at the tissue, cellular and subcellular
levels (Lloyd et al. 2008); and Ramis-Conde et al.’s hybrid
discrete-continuum model which looked at tissue invasion
by cancer cells (Ramis-Conde et al. 2008). Models focus
on different aspects of tumour growth (including the use of
the glycolytic phenotype (Gerlee and Anderson 2008),
evolution of cell motility (Gerlee and Anderson 2009) and
confined environments (Gevertz et al. 2008)) and employ
different modelling approaches [mathematical, (Hirata
et al. 2010; Ramis-Conde et al. 2008), hybrid, (Ribba et al.
2004; Gerlee and Anderson 2007), agent-based (Macklin
et al. 2012; Sun et al. 2012)]. Readers who wish a broader
prospective are directed to the following review articles:
(Anderson et al. 2008; Anderson and Quaranta 2008;
Rejniak and Anderson 2011).
Currently the state of the art in cancer modelling is
spread across different modelling techniques. A recent
review paper looking at cancer invasion discusses the use
of both hybrid discrete-continuous (HDC) models and
immersed boundary models of a cell (IBCell). HDC allows
for cells to be modelled discretely but microenvironmental
variables such as nutrients and oxygen to be modeled using
reaction-diffusion equations. The IBCell model is benefi-
cial for capturing the morphology of a tumour cell as the
cells in this model are deformable (Kam et al. 2012). In
addition to these two types of agent based models, cellular
automaton (CA) models are also used frequently. Gerlee
and Anderson created an evolutionary hybrid cellular
automaton model where the cancer cells are modelled
using cellular automata to capture the behaviour of the
tissue as a whole, while using an artificial neural network
for cell decisions (Gerlee and Anderson 2007). This type of
hybrid cellular automaton model has recently been built on
by Shrestha et al. who used a similar model to look at
large-scale growth of tumours (Shrestha et al. 2013).
Recently, CA models have been used to look at the hall-
marks of cancer (Abbott et al. 2006; Basanta et al. 2011;
Santos and Monteagudo 2012) as proposed by Hanahana
and Weinberg (Hanahan and Weinberg 2000, 2011).
Today survival rates and treatment options for cancers
vary widely, largely due to the vast differences among
cancers including location, size, aggressiveness, ability to
spread and symptoms. Hanahan and Weinberg proposed
that almost all cancers actually share eight phenotypic
changes and two unique characteristics: SELF SUFFICIENCY IN
GROWTH SIGNALS; IGNORING GROWTH INHIBITION; AVOIDANCE OF
PROGRAMMED CELL DEATH (APOPTOSIS); LIMITLESS REPRODUC-
TIVE POTENTIAL; SUSTAINED ANGIOGENESIS; TISSUE INVASION AND
METASTASIS; REREGULATED METABOLISM; EVADING THE IMMUNE
SYSTEM; INFLAMMATION; and GENETIC INSTABILITY (Hanahan
and Weinberg 2000, 2011). The ubiquitous nature of these
hallmarks in cancer suggests that treatments able to target
them may be useful against multiple types of cancer.
Both Abbott et al. and Santos et al. have developed
models looking at these hallmarks (Abbott et al. 2006;
Santos and Monteagudo 2012; Monteagudo and Santos
2012, 2013, 2014). Abbott et al. primarily focused on
looking at the order in which hallmarks were acquired in
the growing tumour. Abbott’s results differed from the
pathway to cancer proposed by Hanahan and Weinberg, as
did the results of an ordinary differential equation model
looking at the pathway (Spencer et al. 2004). Abbott’s
model was an agent based model that simulated the pro-
gression of cancer from a single healthy cell to a tumour
with at least 90 % cancer cells. They found that hallmarks
that confer an advantage to all cells (such as SUSTAINED
ANGIOGENESIS which creates blood vessels carrying oxygen
into the tumour which all nearby cells can benefit from), do
not dominate a cancer clone, whereas hallmarks such as
LIMITLESS REPLICATION appear early and dominate as they
turn over very quickly.
Santos et al. built on the work of Abbott by using a
similar modelling approach, but focused on the impact of
removing different hallmarks on tumour growth. They
investigated how critical to growth each hallmark was by
removing it from the system and comparing the total
number of cancerous and healthy cells present with and
without the hallmark. They used a cellular automaton
model which determined cell division and apoptosis (pro-
grammed cell death) based on internal rules and acquired
hallmarks. They found that with high mutation rates, the
most critical hallmark is APOPTOSIS, while in tumours with
little room to grow the IGNORE GROWTH INHIBITION hallmark
proved most impactful on overall growth.
We have used model parameters and methods similar to
those outlined in Abbott et al.’s work to build upon Santos
et al.’s hallmark relevance study. We have implemented
five of the six original hallmarks as well as two of the
newly introduced hallmarks and enabling characteristics
(focusing on those relevant during initial tumour growth),
and knocked them out in pairs to see which have the
greatest combined effect.
Henderson stated that ‘‘in the most general sense,
combinations of therapies, whether drugs and/or other
modalities, will always play an important role in the
management of diseases for which there exists no single
specific and totally effective treatment’’ (Henderson and
Samaha 1969). Combination treatment involves pairing
multiple treatments with the hope that two in combination
will not just be an additive advantage but a multiplicative
one. Targeted therapy involves identifying key pathways
involved in cancer progression and creating drugs to target
these pathways. This model simulates targeted combination
16 J. Butler et al.
123
therapy as we remove key cancer properties (hallmarks) in
pairs and compare cancer growth rates to tumours with all
hallmarks active. We hypothesize that knocking out pairs
of hallmarks will not necessarily have the additive effect of
knocking the hallmarks out separately but rather will
sometimes have an even greater, potentially multiplicative,
combined impact. The following sections include: a brief
summary of each hallmark; the event process; pseudocode
for the simulation; Lattice-Boltzmann implementation
details; parameters used; results and discussion.
2 Methods
We have chosen to model two dimensional cancer growth
where the biological cells are represented by cellular
automata and the oxygen in the environment is modelled as
a two-phase fluid using the lattice Boltzman method. Most
models in the literature currently restrict themselves to two
dimensions as it is more computationally feasible and since
cancer does not grow in a sphere but rather an oblate
spheroid. Our 2D simulation is easily compared with both
existing models and 2D biopsy slices. Here we will present
a high level outline of the method, and each section will be
covered in more detail below. Pseudocode describing the
simulation is provided in Table 2. The simulation begins
with a single healthy cell at the center of a 2-dimensional
grid. An event queue keeps track of cellular events, and
initially a single mitotic event is placed on the queue for
the healthy cell. Each event popped from the queue is
another loop in the model and puts that cell through a life
cycle. The cell is checked for whether it still has enough
oxygen to survive, is in a location with growth factor, has
access to blood, has space to grow, and has sufficiently
long telomeres. If all of these checks are successful, or if
mutations confer these abilities, the cell enters a mitotic
event. This creates a daughter cell and potentially intro-
duces mutations into the daughter or parent. Both cells
have events scheduled for some point in the future and are
added to the event queue, then the next event is popped.
Oxygen is consumed by cells when they divide or every 25
time steps if they are not actively dividing. The following
sections include: a brief summary of each hallmark; the
event process; pseudocode for the simulation; Lattice-
Boltzmann implementation details; parameters used;
results and discussion.
2.1 Modelling the hallmarks
The ‘‘hallmarks of cancer’’ proposed by Hanahan and
Weinberg are changes to cell phenotype (characteristics of
the cell based on its genotype and the environment—in our
model, phenotype is the collection of hallmark mutations a
cell has along with parameter values) that seem to be con-
sistent across a variety of cancers (Hanahan and Weinberg
2000, 2011). These hallmarks give a structure and common
signature to a disease that is actually a combination of hun-
dreds of different types of diseases. We have simulated 5 of
the 6 original hallmarks and two of the recently added
characteristics and hallmarks that were described in (Hana-
han and Weinberg 2011). This model is specifically focused
on the pre-metastatic growth, when a patient has the greatest
chances of survival. Therefore, we have not modelled the
sixth hallmark, tissue invasion and metastasis. To keep our
results comparable with previous work in this field, we have
not included inflammation or energy metabolism in our
model. Our model is inspired by work in artificial life where
agent based and mathematical models have been used to
simulate cancer growth and angiogenesis (Maley and Forrest
2000; Bentley et al. 2008). Here we will briefly describe each
hallmark put forth by Hanahan and Weinberg that we are
including in this model, as well as their implementation. At
the end of this section pseudo code describing the cell life-
cycle is included.
2.2 Self-sufficiency in growth signals—hallmark
symbol: SG
Normally, cells are generally in a quiescent state where
they are functioning but not actively proliferating. In order
for a cell to become mitotically active, it needs mitogenic
growth signals, which stimulate it to move from the qui-
escent state to a dividing one. Normal, healthy tissues
regulate the creation and release of growth signals very
carefully, balancing the number of actively dividing cells
so no area is overburdened with resource requests. Cancer
cells de-regulate these signals. In fact, self-sufficiency in
growth signals is said to be the most fundamental trait of
cancer cells (Hanahan and Weinberg 2011).
The deregulation of these signals in cancer is fairly well
understood (Witsch et al. 2010; Perona 2006). Cancer cells
can sustain their growth through a variety of mechanisms
including:
• sending growth signals to surrounding cells which
reciprocate by sending even more growth factors;
• increasing their own cell-surface receptors for growth
signals so that normal levels of signal can have an
enhanced effect;
• activation of growth pathways downstream of signal
reception, which enhances proliferation but also
reduces their dependency on external stimuli;
• interference with negative feedback loops which nor-
mally lessen signals and therefore assist in maintaining
homoeostasis. Hanahan and Weinberg have predicted
that ‘‘compromised negative-feedback loops’’ will be
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found to be ‘‘wide spread among human cancer cells’’
(Hanahan and Weinberg 2011). They also believe cancer
cells may use this ability to disturb feedback loops to gain
resistance to drugs which target cell cycle signalling.
It is hypothesized by Hanahan and Weinberg that cells
may have built-in safety mechanisms to avoid excessive
growth, and they postulate that cancer may be involved in a
delicate trade-off between increased signalling for fast
growth and not growing so fast as to trigger interference
from safety mechanisms (Hanahan and Weinberg 2011). It
is also possible that cancer cells could somehow be deac-
tivating these safety mechanisms.
In order to model this hallmark, we have programmed
healthy cells such that they are only able to divide within a
certain area of the total growth environment. Healthy cells
can only divide up to some predefined limit, which is akin to
an area with growth factor present. In certain areas (outside
the limit) there is not enough growth factor to signal prolif-
eration, and therefore healthy cells become non-proliferative
in this area. Cancer cells however can obtain the SUSTAINED
GROWTH (SG) mutation, allowing them to actively divide
outside of the predefined boundary, modelling the ability to
initiate growth themselves via a variety of mechanisms.
2.3 Ignore growth inhibition—hallmark symbol:
IGI
Coupled with a tissue’s tight regulation over growth
inducing mechanisms, tissues also have strong negative
regulation over cell growth, actively suppressing it as
opposed to passively not taking part due to the absence of
growth promoting factors. The genes which do this are
often referred to as tumour suppressor genes as they can
actively limit cell growth and proliferation through a
variety of mechanisms including stopping the cell cycle
and cell-cell contact inhibition.
While there are a variety of ways cell growth can be
negatively controlled, we have chosen to look at the impact
of pressure exerted on cells by other cells. When cells grow
together the cell-to-cell contact has an inhibitory effect on
growth. This mechanism, called contact inhibition, is often
turned off or perhaps ignored in many cancer cells. An
example of a gene involved in this pathway is the NF2 gene,
the loss of which triggers human neurofibromatosis, a dis-
ease which deposits tumours throughout a patient’s body.
The gene product of NF2, Merlin, strengths cell-cell adhe-
sion and also sequesters growth factors, limiting cell growth.
In order to model cancer’s ability to ignore anti-growth
signals, we have implemented an empty space requirement
for growth. This models one of cancer’s anti-growth ave-
nues—avoid contact inhibition. In this model, healthy cells
stop actively growing once there is no more space available
on the lattice. Cancer cells in our system can have the
IGNORE GROWTH INHIBITION (IGI) hallmark activated which
allows cells to grow even without space (thereby modelling
the impact of mutations which cause a cell to ignore con-
tact inhibition). These cells have a ‘‘competition’’ factor
(c). If a cell with the IGI hallmark attempts to grow and is
out of space, they compete with cells around them and can
potentially take over the space another cell is occupying in
order to grow. Each time a cell competes (done once every
attempt to divide without space), the cell has a 1 / c like-
lihood of successfully gaining the space, where c is the
competition factor mentioned in Table 1.
2.4 Resisting cell death—Hallmark symbol: IA
Apoptosis, or programmed cell death, is a normal process
in animal tissue. Apoptosis assists in keeping the balance of
healthy living cells with dead or dying cells, keeping cell
populations in check and dealing with damaged or old
cells. In addition to helping maintain balance, it is also a
Table 1 Parameters used in simulations
Description Symbol Value References
Initial telomere length t 100 Abbott et al. (2006)
Evade apoptosis factor ev 10 Abbott et al. (2006)
Mutation rate m 500 Chosen to lay between two used in Santos and Monteagudo (2012)
Random death rate d 10000 Simulation
Competition likelihood c 10 Abbott et al. (2006)
Angiogenesis immunity ai 10 Simulation
Avoid immunity aip 10 Simulation
Immunity death i 1000 Simulation [equal to random cell death in Santos and Monteagudo (2012)]
Genetic instability factor gif 10 Simulation
Blood density qB 300 mol/m3 Erbertseder et al. (2012)
Boundary oxygen density qO 9 mol/m3 McArdle et al. (2005)
Thermal diffusivity D 0:134 mm2 s1 Valvano et al. (1985)
18 J. Butler et al.
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safety mechanism which prevents damaged cells from
passing on damage (Lowe et al. 2004; Evan and Littlewood
1998).
Apoptosis has been found to be triggered by different
events, many of which are common during the progression
from normal, healthy cell to cancerous cell, such as high
levels of oncogene expression and DNA damage. Although
it is known that DNA damage and oncogene overexpres-
sion can lead to cancer, which should trigger apoptosis, it
has also been found that cancer cells sometimes manage to
avoid apoptosis (Hanahan and Weinberg 2011).
Various cell conditions leading to apoptosis have been
identified, with one of the most notable being DNA dam-
age (Junttila and Evan 2009). Major DNA breaks or
chromosomal abnormalities are sensed by tumour-sup-
pressor protein 53 (p53, encoded in gene TP53) which can
in turn activate apoptosis if the damage cannot be fixed.
While cancer cells evolve many mechanisms to avoid
apoptosis, one of the most common is loss of TP53 func-
tion (found to be gone in 50 % of all cancers). This allows
a cell to build up DNA damage unchecked which can lead
to additional mutations and passing down of damaged
DNA.
We have chosen to model the apoptotic pathway pri-
marily as a sensor for DNA damage. Once a healthy cell
has sustained any mutations, it is possible for it to enter the
apoptotic state (simulating the cell being killed by apop-
tosis). Since apoptosis can be activated due to genetic
damage, the chances of a cancer cell dying via apoptosis
increases with each subsequent mutation (in our model). A
cell has a m/a probability of being killed by this mecha-
nism, where m is the number of mutations already sus-
tained, and a is an apoptosis chance variable contained in
each cell (see Table 1 for exact parameters). Cells with a
mutation in this mechanism cannot die by apoptosis,
regardless of the number of mutations acquired. This
AVOIDS APOPTOSIS mutation is referred to as AA throughout
the paper.
2.5 Enabling replicative immortality—Hallmark
symbol: IT
Most normal healthy cells have a limit to how many times
they can divide before they enter a viable but non-prolif-
erative state called senescence. Healthy cells that manage
to avoid senescence often instead enter a crisis state, end-
ing with cell death. In contrast, cancer cells seem to require
unlimited replication to grow into a tumour of macroscopic
size. When cells are propagated in culture, leading to
senescence, and then for some to crisis, many of the cells
die. At this point it occasionally happens that a cell line
comes up displaying this unlimited replication, effectively
becoming immortal, continuing to grow without hitting
senescence or crisis (Hanahan and Weinberg 2000, 2011).
It is believed cells have a feature which only allows
them a certain number of replications—this feature is the
telomere. Telomeres are segments of DNA made up of
multiple repeating 6-nucleotide segments capping the ends
of chromosomes. DNA replication is not a perfect process
and always results in the loss of some material at the ends
of chromosomes. Telomeres protect the ‘‘necessary’’ DNA
by themselves being shortened at each replication. Even-
tually however they become too small to effectively protect
the DNA and at this point it is believe senescence can be
triggered.
Telomerase is a DNA polymerase that builds these
telomeres. Normally it is not active in healthy cells, how-
ever it is found to be turned on in 90 % of suddenly
immortal cells (Hanahan and Weinberg 2011). Telomerase
then can continuously extend the ends of DNA making it so
they never reach a size small enough to trigger senescence
or crisis. Accordingly, the presence of telomerase is cor-
related with resistance to both of these fates. It is believed
both of these events (senescence and crisis) are natural
barriers to cancer. Rogue cells may develop mutations, be
growing out of control of the body’s signalling, and begin
rapid division. These cells can be abruptly stopped when
their full replicative potential is reached, causing them to
not be able to divide further and not make it to a macro-
scopic tumour. Cells which manage to activate telomerase
however keep their telomeres long enough to avoid
senescence and crisis and therefore forever pass on their
mutations. As such, telomere shortening is thought to be
one of the barriers cancer cells must defeat to progress into
a dangerous tumour (Hanahan and Weinberg 2011). One
particular example supporting this hypothesis is the work
of Artandi and DePinho who found that mice genetically
predisposed to certain cancers had weakened tumourigen-
esis when born without telomerase (Artandi and DePinho
2010).
We have included in our model the ability for a cell to
become immortal. Every cell is equipped with a ‘‘telom-
ere’’ variable that decreases by one with every cell divi-
sion. This variable limits healthy cells to 100 cell divisions
(Abbott et al. 2006). Cells can acquire the IGNORE TELOMERE
hallmark which allows them to effectively ignore this
limitation and not be bound by their telomeres. This
replicates the biological activity of telomerase which
continues increasing telomeres after they are shortened,
preventing their length from impeding growth. Cells with
the IGNORE TELOMERES (IT) hallmark activated can divide
Halting the hallmarks: a cellular automaton model of early cancer growth inhibition 19
123
forever, regardless of telomere length, so long as all other
required conditions are met (oxygen, space, etc).
2.6 Inducing angiogenesis—Hallmark symbol: A
Vasculature, the system of blood vessels in the body,
serves two major purposes for cell groups: delivering
nutrients and oxygen, and removing waste products and
carbon dioxide. Both healthy and cancerous cells depend
on and need this system. Typically, vasculature is quite
stable. It is originally developed during embryogenesis,
when the processes of vasculogenesis (the birth of new
endothelial cells and their development into tubes) and
angiogenesis (sprouting) occur. After embryogenesis is
complete, angiogenesis is only turned on transiently during
wound healing and as part of the female reproductive
cycle. A key early development in tumour growth is the
activation of this normally quiescent angiogenic process,
causing new vasculature to sprout towards and even into
tumours (Hanahan and Weinberg 2000, 2011). This is
dangerous as it not only provides the tumour with fresh
oxygen, nutrients, and waste removal, but also gives it a
system to use to travel through the body.
When angiogenesis is induced in tumours it often results
in poorly set up vasculature with issues such as leakiness,
erratic blood flow and excessive and convoluted branching.
While this process was previously thought to occur later in
tumour development, such as once the tumour was rapidly
growing and macroscopic in size, research in the past two
decades has found it can begin as early as the pre-malig-
nant microscopic stage of growth (Raica et al. 2009).
Tumours exhibit widely varied tumour-induced vascu-
lature, even within the same organ. For example, adeno-
carcinoma of the pancreatic ducts is hypovascularized
(Olive et al. 2009), while pancreatic neuroendocrine car-
cinomas can be densely vascularized (Detjen et al. 2010).
The variety of tumour induced angiogenesis seen suggests
that angiogenesis is initially switched on, but complexly
regulated and impacted throughout tumour growth. While
the mechanism of angiogenesis switch activation can vary,
the net result is a common inductive signal. In some cases
oncogenes activate angiogenesis. These also can stimulate
proliferation which means other unique hallmarks (such as
sustained growth) can possibly be activated by the same
rogue players.
Since it is believed angiogenesis is at least initially
switched on in tumour growth, and this model aims to
simulate early tumour growth, we have included this
hallmark. In the simulation, angiogenesis is modelled at a
very basic level. Cells that have the INDUCE ANGIOGENESIS
(A) hallmark activated are thought to be on the path of new
vasculature. In the simulation, every lattice location has an
associated oxygen value that changes over time based on
consumption and supply, and is modelled using Lattice
Boltzmann methods (LBM) (full implementation details on
this model are described in Sect. 3). At each division a cell
checks if it has enough oxygen to survive by checking with
the lattice Boltzmann simulation to determine how much
oxygen is present where it is located. If a cell does not have
enough oxygen it either becomes quiescent or dies (de-
pending on how much oxygen is present). However, if it is
on the path of vasculature because it is inducing angio-
genesis, it is getting oxygen directly from the vasculature
so it does not require enough oxygen in its lattice cell as
calculated by the LBM. Neighbours of cells on the new
vasculature also benefit from this via diffusion from the
vasculature and are able to survive in places where there
would not otherwise be enough oxygen provided by the
original healthy vasculature.
In this model angiogenic cells also have a higher chance
of being killed by the immune system, as immune cells
travel via the vasculature. Angiogenic cells and their
neighbours have a ðaiÞ  ð1=iÞ chance of being killed by the
immune system at each replication step, where (ai) is the
angiogenesis immunity parameters and i is the immune
death probability parameter (Table 1).
2.7 Genetic instability—Hallmark symbol: GU
Cancer cells acquire the above mentioned hallmarks in
large part because of successive changes to the genome of
neoplastic cells (Hanahan and Weinberg 2011). Some
mutational changes will confer an advantage to the cell or
cells, allowing them to grow and dominate in an environ-
ment. Therefore, the many steps from normal cell to
cancerous cell, and the subsequent stages of tumour
growth, can be viewed as the successive accumulation of
favourable chance mutations each creating a new cell clone
group. However, not all clonal expansions need be caused
by mutations, as research has shown that epigenetic
changes can also impact gene expression (Berdasco and
Esteller 2010; Jones and Baylin 2007).
Many innate cell systems are able to detect and repair
DNA damage; consequently, the number of spontaneous
mutations in a cell generation tends to be low. Cancer cells
however often have higher than normal mutation rates,
which can be achieved in a variety of ways. There can be
an increased sensitivity to mutagenic agents or breakdown
in any of the genetic maintenance machinery or pathways.
Also, a disturbance in the cell machinery that detects and
fixes mutations (for example, TP53, mentioned earlier) can
lead to an increased mutation rate. The process of detecting
20 J. Butler et al.
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and fixing DNA damage is complex, and so has a lot of
potential places breakdowns can happen, such as:
• Machinery that detects damage and activates repair
pathways;
• Machinery that repairs DNA;
• Machinery that kills a cell if too much damage is
acquired;
• The pathways involved with the inactivation and
interception of mutagenic molecules.
Other cell components can be included in the list of
‘‘caretakers’’ that watch over the genome. Some research
found that there may even be certain areas of the genome
where aberrations are likely to lead to neoplastic growth,
an interesting observation made after seeing recurrence of
specific amplifications and deletions at certain sites in
breast cancer (Korkola and Gray 2010).
Currently it is known that the genetic changes in cancer
vary across tumours, tissues and types, however one thing
that is agreed upon is the vast array of cell maintenance and
repair mechanisms that can be damaged as well as the
prevalence of copy number changes in cancers. These
widespread changes point to genome instability as an
enabling characteristic of cancer in general, and possibly
one that is causing the acquisition of cancer hallmarks
(Hanahan and Weinberg 2011).
Working with this belief, that genome instability could
cause cells to acquire some hallmarks, we have added it as
an enabling characteristic in this cancer simulation. While
there are many different pathways and mechanisms that
can be impacted in cancer growth and cause genetic
instability, the end result is a genetically unstable cell
which has a higher likelihood of mutation. We model this
characteristic with the GENETICALLY UNSTABLE hallmark
(GU) which when active increases the chances of mutation
in each mitotic event by a factor of ð1=gifÞ where gif is the
genetic instability factor parameter (Table 1). Modelling it
in this way allows for hallmarks to still be acquired
spontaneously due to any number of factors, but also
allows cells to accumulate mutations more quickly if they
are genetically unstable.
2.8 Evading immune destruction—Hallmark
symbol: AI
Listed as an ‘‘emerging hallmark’’ in the updated cancer
hallmarks paper, the ability for cancer to seemingly evade
destruction by the immune system is an unresolved issue
that appears to play a large role in cancer growth (Hanahan
and Weinberg 2011). It has long been believed that the
immune system is like a constant surveillance system,
watching the body for signs of foreign cells or incipient
cancer cells, eradicating them if they are found. By this
logic, cells that manage to grow into full macroscopic
tumours must have somehow avoided detection or
destruction by that same system.
One piece of evidence in the argument that the immune
system is involved in the early detection and eradication of
cancer cells is the fact that individuals who are immuno-
compromised have a much higher incidence of certain
cancers (Vajdic and Leeuwen 2009). However many of
these are cancers caused by viruses, and so it may seem
that perhaps the role of the immune system in cancer
prevention is just minimizing the viral load on a body.
Recently however, some studies have shown that even in
non-virus-induced cancer, the immune system still plays a
significant role as a barrier to cancer progression (Hanahan
and Weinberg 2011).
Studies with genetically engineered mice back up this
claim. Mice that have been engineered to lack various
pieces of the immune system had an increased incidence of
tumour formation. Mice that were engineered to be defi-
cient in multiple pieces of the immune system had even
higher rates of cancer (Teng et al. 2008; Kim et al. 2007).
Hanahan and Weinberg believe there is some evidence
of antitumour immunity but that it has yet to be proven
ubiquitously enough to be considered a core hallmark and
as such have set it as an ‘‘emerging hallmark’’. We have
chosen to include emerging hallmark AI in this study, as
we are interested in a high-level, abstract model. We could
assume this general model is of a type of solid mass tumour
that is affected negatively by the immune system, as many
cancers have been shown to be. This simulation has a very
simple, basic model of immune system surveillance. In the
model, cells which have sustained mutations have the
possibility of being killed by the immune system at every
life cycle (a probability of 1/i where i is the immune death
parameter in Table 1). We then model cancer’s ability to
possibly avoid this with the AVOIDS IMMUNE SYSTEM hallmark
(AI) which, when activated, lowers the probability of a
cancer cell being killed by the immune system by a factor
of aip, the avoids immune system parameter (Table 1).
2.9 A note on hallmarks not included
This model specifically includes 5 of the original 6 hall-
marks of cancer, one of the two emerging hallmarks, and
one of the two enabling characteristics. The choice of what
to model was informed by the scope and type of study, the
biological relevance at the early growth phase, and the
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computational and modelling feasibility. Those interested
in learning more about the hallmarks not included (or any
hallmarks) are directed to the revised Hallmark paper,
Hallmarks of cancer: The next generation (Hanahan and
Weinberg 2011) and the papers referenced therein.
Firstly, we left out the ‘‘tissue invasion and metastasis’’
hallmark from the original hallmark paper (Hanahan and
Weinberg 2000). This particular cancer simulation is
focused on the early, pre-metastatic growth phase of can-
cer. We are interested in early growth, the appearance of
the hallmarks, the time when tumours reach visible size
and what hallmark-stopping efforts are most useful at this
time. Patients whose tumours are found before they spread
have a much better chance of survival and we are interested
in this early phase of growth. This simulation looks
specifically at early tumour growth and the development of
the primary tumour, and as such does not include invasion
or metastasis in the simulation.
The enabling characteristic we did not include is ‘‘tu-
mour promoting inflammation’’. Hanahan and Weinberg
point out that inflammation is sometimes present at very
early stages of neoplastic progression, and has been found
to be clearly capable of assisting in the progression from
incipient neoplasias to fully functioning cancer tumours.
Also, some inflammatory cells release reactive oxygen
species which are mutagenic to the surrounding cells,
possibly assisting these cells in gaining advantageous
mutations. As such, Hanahan and Weinberg have classified
inflammation as an ‘‘enabling characteristic’’ of cancer,
however they stated that of the two enabling characteris-
tics, the most prominent is genomic instability. We have
chosen not to include this characteristic in our simulation.
We are modelling early cell growth, which has been shown
to sometimes have inflammation present, but not always.
Also, the role of inflammation is still largely unknown.
Many of the cell types that lead to inflammation, such as
cells of the innate immune system, play a dual role of
assisting in cancer development and trying to stop it.
Inflammation appears to be involved in a host of devel-
opments, specific to what cells are present, the microen-
vironment, etc. As such, there is no obvious single impact
on early tumour growth that can be abstracted to a
parameter that could be modelled in the type of high level
model we are interested in studying. In the future adding a
microenvironment at a lower level of abstraction would be
beneficial and would allow the addition of some inflam-
matory responses.
Lastly we have not modelled the emerging hallmark of
‘‘deregulated cellular energetics’’. This potential hallmark
involves a cancer cell’s ability to change their energy
metabolism pathway from the high efficiency aerobic res-
piration, to the lower efficiency anaerobic respiration. As
this is an emerging hallmark, Hanahan and Weinberg have
not decided that it is common enough to be a full hallmark.
Also, this high level model is only looking at one aspect of
the tumour microenvironment—the impact of oxygen
availability on the hallmarks. We are not specifically
modelling ATP creation or glucose, and as such we have
not included this emerging hallmark.
2.10 Event queue
Mitotic events are the driving force in this model. An event
queue keeps track of all events scheduled for the simula-
tion. Initially, the cell has a mitotic event scheduled for 5–
11 time steps in the future. When the event is popped the
time is checked. If the time for the event is beyond the
current time in the simulator the current time is updated. If
the cell is to grow in a North, East, South or West direction,
the time is scheduled 5–11 time points in the future (chosen
by random number from a uniform distribution). If the cell
is growing on a diagonal on the grid then the event is
scheduled for 7–14 (
ffiffiffi
2
p
of the normal mitotic time) to
account for the increase in spatial distance.
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2.11 Lifecycle psuedocode
3 Lattice-Boltzmann implementation details
Lattice-Boltzmann algorithms (Chen and Doolen 1998;
Succi 2001), have become increasingly popular as methods
used to model coarse-grained fluid dynamics. These
methods use a discretization of time, space, as well as
velocity in order to solve for the motion of a set of partial
distribution functions, fiðx; tÞ, each corresponding to a
discrete velocity vector, ei, which evolve according to a
discretized version of the linearized Boltzmann equation.
Macroscopic fluid quantities are then determined via
moments of these distribution functions.
In order to model the transport of oxygen dissolved in
blood, we use a two component lattice-Boltzmann algo-
rithm. Here, the quantities of interest are the total density
q ¼ qB þ qO which should satisfy both the continuity and
1: firstCell ← Cell
2: time ← 0
3: firstCell.scheduleMitoticEvent()
4: eventQueue.push(firstCell)
5: S ← 0
6: while eventQueue not empty do
7: currentCell ← eventQueue.pop()
8: if currentCell.isAlive then
9: time ← currentCell.time()
10: dead ← currentCell.died {check for random cell death.}
11: if currentCell.isMutated then
12: apop ← currentCell.apoptosis {check for death via apoptosis if cell
is mutated. Avoided if apoptosis hallmark is on}
13: end if
14: cangrow ← false
15: if selfGrowthHall or withinGrowthRange then
16: cangrow ← true
17: end if
18: if spaceToGrow then
19: space ← true {If ignore growth inhibition is on, it can compete for
space if no space available}
20: end if
21: telo ← false
22: if currentCell.getTelomere > 0 or currentCell.ignoresTelomereHallark
then
23: telo ← true
24: end if
25: if currentCell.withinBlood or currentCell.isOrWithinAngiogeneic
then
26: blood ← true
27: end if
28: if currentCell.killedByImmune ! = true or currentCell.avoidsImmune
then
29: stillAlive ← true
30: end if
31: if currentCell.enoughOxygen then
32: oxygen ← true
33: end if
34: if cangrow and space and telo and blood and stillAlive and oxygen
then
35: daugtherCell ← currentCell.mitosis {daughter cell may be mu-
tated during mitosis event}
36: currentCell.mitosisOccured() {opportunity for mutation during a
mitosis event}
37: currentCell.scheduleMitoticEvent()
38: daughterCell.scheduleMitoticEvent()
39: eventQueue.push(daughterCell, currentCell)
40: end if
41: end if
42: end while
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Navier–Stokes equations, and the density difference
between the two components / ¼ qO  qB, which will
evolve according to a convection–diffusion equation. In
these expressions, qO corresponds to the density of oxygen
in the blood, and qB is the density of the remaining blood
constituents. In order to model these two quantities we
follow the binary fluid approach of (Orlandini et al. 1995;
Swift et al. 1996), and introduce two sets of distribution
functions, fi and gi, whose moments correspond to the
physical variables,
q ¼
X
i
fi
qua ¼
X
i
fieia
ð1Þ
/ ¼
X
i
gi; ð2Þ
where u is the local fluid velocity. The time evolution of
these distribution functions is governed by the following
discretized Boltzmann equations,
fiðxþ eiDt; t þ DtÞ  fiðx; tÞ ¼ 
Dt
sq
fiðx; tÞ  f eqi ðx; tÞð Þ
giðxþ eiDt; t þ DtÞ  giðx; tÞ ¼ 
Dt
s/
giðx; tÞ  geqi ðx; tÞð Þ
þ hiðx; tÞDt:
ð3Þ
The first term on the right hand side describes a single time
relaxation towards the equilibrium distribution functions,
f
eq
i and g
eq
i (Bhatnagar et al. 1954), while hi is a forcing
term we have introduced in order to remove oxygen locally
from the system when it is consumed by the cancer cells.
To model these equations we use a nine velocity, 2D
algorithm with velocity vectors,
ei ¼ ð0; 0Þ; ðvc; 0Þ; ð0;vcÞ; ðvc;vcÞ½ ; ð4Þ
where vc ¼ Dx=Dt, with Dx and Dt corresponding to the
lattice spacing, and timestep respectively.
In order to satisfy conservation of mass and momentum
we choose the equilibrium distribution functions according
to,
X
i
f
eq
i ¼ q
X
i
f
eq
i eia ¼ qua
X
i
g
eq
i ¼ /
ð5Þ
X
i
g
eq
i eia ¼ /ua; ð6Þ
and define the higher moments and forcing term by the
following equations,
X
i
f
eq
i eiaeib ¼ Pab þ quaub
X
i
g
eq
i eiaeib
X
i
hi ¼ F
X
i
hieia ¼ 0:
ð7Þ
Here Pab is the pressure tensor, C is the mobility, which is
related to the diffusion constant, l is the chemical potential
difference between the fluid components, and F is an
oxygen sink term describing the amount by which /
changes at a given timestep. With these choices, a Chap-
man-Enskog expansion of our Boltzmann equations
[Eq. (3)] can be shown to reproduce the continuity and
Navier–Stokes equations,
otqþ oaqua ¼ 0
qotua þ qubobua ¼ obPab þ gr2ua;
ð8Þ
as well as a convection–diffusion equation with oxygen
sink term, F,
ot/þoað/uaÞ¼ ðs/Dt=2Þ Cr2loa
/
q
obPab
  
þF:
ð9Þ
to second order in the derivatives. Here, the viscosity, g, is
defined according to qðsqDt=2Þv2c=3. For the pressure,
Pab, and chemical potential difference, l, we use the
equations given in (Orlandini et al. 1995; Swift et al.
1996), which were derived based on a free energy
description of the fluid mixture,
l ¼  k
2
/
q
þ n
2
ln
qþ /
q /
 
Pab ¼ qnþ /l½ dab:
ð10Þ
Here k and n are parameters determining the state of the
system; for n\k=2 phase separation of the two compo-
nents occurs. We therefore always work in a regime where
n[ k=2 and the oxygen remains mixed in the blood. In this
framework, the diffusion constant for the model, D, is
given by,
D ¼ ðs/  Dt=2ÞCk
2q
: ð11Þ
For the lattice-Boltzmann algorithm, we use a density of
qB ¼ 300 mol/m3 (Erbertseder et al. 2012) throughout the
simulation domain, and set the density of oxygen to qO ¼
9 mol/m3 at the boundary, representing a continual supply
of oxygen to the system. We choose a diffusion constant,
D ¼ 0:134 mm2=s (Valvano et al. 1985), corresponding to
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the thermal diffusivity of colon cancer. The oxygen grid is
updated every 25 time steps (time in the cellular automata
model) and each cell at that point consumes oxygen if it
has not consumed already during a mitotic event. The
consumption level for normal cancerous cells is 0.019. The
lattice Boltzmann grid is finer than the CA grid (a ration of
1 cancer cell to 9 lattice Boltzmann cells), and so at each
time step of the cancer cells, each cancer cell calculates the
amount of oxygen present in all lattice Boltzmann cells
mapped to it and gets a total oxygen value. These are
dimensionless and are parameters chosen by fixing the
consumption and diffusion rates, and iteratively determin-
ing what requirements gave the most physiologically rel-
evant results.
3.1 Parameter values
Parameters (Table 1) for the model were either chosen from
the literature or by searches of the parameter space. Param-
eters used in the models by Abbott (Abbott et al. 2006) and
Santos (Santos and Monteagudo 2012) were held constant
(except mutation rate which was selected to be between the
two values used by Santos) and other parameters were varied
iteratively. The output (tumour size, shape, composition and
cell type ratios) was examined for concordance with in vivo
tumours. The tumours resemble the classic solid mass
tumour structure of a necrotic core with a quiescent rim and
proliferating rim (Folkman and Hochberg 1973; Sutherland
et al. 1986). The tumours also grow to roughly 2–2.5 mm
before overwhelming the nutrients available and needing
their own vasculature (Folkman 1971) and then grow to a
maximum of 5.5 mm. All calculations were done using an
average cell diameter of 25 lm (Tom et al. 1976). The
tumours grow to this final size over a period of approximately
2 years, assuming a cell division time of 16–24 h. This is in
line with growth times for fast growing tumours, which reach
clinically detectable size (0.2 cm to 1 mm) within 2 years
(McArdle et al. 2005).
4 Results
With all hallmarks active, every simulation run produced a
tumour using parameters described in Table 1. A ‘‘tumour’’
is classified as a mass in which 99 % or more of its alive cells
have at least one mutation. The growth over time for a sim-
ulation with all hallmarks available can be seen in Fig. 1.
Figure 1a shows total cell counts throughout growth.
Initially healthy cells grow rapidly, however around step 20
they sharply decline. Then, around step 25 cancer cells
rapidly start to increase. This corresponds to a sharp
increase in angiogenic cells as well as cells that avoid
apoptosis, and relatively stable numbers of healthy cells.
Figure 1c–h shows the images produced from the same
simulation. It can be seen in Fig. 1c that initially healthy
cells dominate the clone. Death is occurring, most likely
due to random cell death or the initial fast killing of any
cancerous cells by apoptosis and the immune system. By
1d we can already see the emergence of different cancer
phenotypes. There are three major phenotypes present in
the tumour from early on. The center of the tumour also
begins to die at 1d. This is due to a lack of oxygen getting
to the center of the tumour (causing necrosis). At 1g the
outside of the tumour is also dying, as regular cells can go
no further as they are outside the growth factor and blood
range. In 1h we see the tumour is almost entirely cancer-
ous, with a few different phenotypes protruding from the
mass. This ‘‘fingering morphology’’, where the border is
not smooth but rough, is consistent with other models and
histopathological observations (Bello et al. 2004; Ander-
son et al. 2006; Bellomo and Angelis 2008). It is believed
that there are two forms of tumour invasion—either tumour
cells outgrow normal tissue and expand as a bulk mass, or
they form invasive contingents by intermingling with
stromal cells. The fingering morphology is a consequence
of this intermingling (Kam et al. 2012). It has been noted
that this fingering morphology looks like a crab, from
which the word cancer was derived (Kam et al. 2012). The
fingering morphology is correlated with harsher microen-
vironments where only cells with particular phenotypes
survive. This behaviour is evident in our model where
certain subclones and phenotypes dominate the tumour.
Knocking out some hallmark pairs had very little effect
on the growth of the tumour. In fact, knockout pairs SG &
IGI, SG & AA, SG & IT, IGI & AA, IGI & GU, IGI & AI,
AA & GU, AA & AI, IT & GU and GU & AI had no
significant effect (all p values [0.05 using Wilcoxon
signed-rank test Bonferroni corrected for multiple com-
parisons) (see Fig. 2b, c for examples of final simulation
image when cancer took over despite hallmark pair
knockouts). Other pairs of hallmarks had such a large effect
that a cancerous tumour never took over and the simulation
ended prematurely as not enough cells survived. The nor-
mal cells continued to grow to the edge of the growth factor
barrier, and then eventually consumed all of the oxygen in
the system and the healthy cells died off. This can be seen
in Fig. 2d, e. The following hallmark pairs significantly
(p = 0.0004 using Wilcoxon signed-rank test, Bonferroni
corrected) decreased cancer growth: SG & A, SG & GU,
SG & AI, IGI & A, AA & A and A & GU. Other pairs, AA
& IT and A & AI had a smaller but still significant effect
(p ¼ 0:017 and p ¼ 0:019 respectively using Wilcoxon
signed-rank test, Bonferroni corrected).
The effect of various hallmark pairs can be seen in
Fig. 3. This shows that some hallmark knockouts (A &
GU, IGI & A, IT & A, SG & A, A & AI, SG & AI) do not
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result in a tumour. Cancer growth is fairly consistent across
all of the simulations, regardless of knockout, until step 20.
Here, all cell populations take a dip however certain sim-
ulations show strong growth after this point. The knockout
pairs listed above however die off at this point, and these
simulations do not result in a cancerous tumour.
Figure 4 shows a histogram of phenotypes that were in
the top 10 phenotypes by cell count during the last stage
of simulation for 14 unique simulations (knockout pairs
that still resulted in a tumour). IDs can be mapped to
phenotype using Table 2. While it is obvious that phe-
notype 0 (dead phenotype) will be present in large
numbers in all runs, it is interesting that phenotype 4 and
132 are also present in every run in large numbers—these
are cells with the ANGIOGENESIS hallmark activated and no
other hallmarks, both alive and dead. Also, by the end of
simulation almost all tumours have a large population of
dead SELF GROWTH cells and AVOIDS APOPTOSIS cells. It is
interesting that alive ANGIOGENESIS cells dominate but dead
SELF GROWTH and APOPTOSIS. Also present in the majority of
simulations in large numbers are dead cells with IGNORES
GROWTH INHIBITION activated and IGNORES TELOMERES acti-
vated, as well as alive cells that are both ANGIOGENIC and
AVOID APOPTOSIS.
Fig. 1 Total cell count for cancerous, non cancerous, and each
hallmark is shown for an entire simulation will all hallmarks available
for activation. a Regular versus cancerous cell growth, b each
individual hallmark growth and total cancer cell growth. c–hSimulation
of a colony of cells with all hallmarks available for activation at event
steps 1–32. Dead cells are black, healthy cells are blue, all other colours
represent some kind of unique cancer phenotype phenotype. Simulation
steps: c 1, d 6, e 12, f 18, g 24, h 32. (Color figure online)
Fig. 2 End of simulation images for four different hallmark-knockout pairs. a No hallmarks knocked out, b IGI & AA, c IGI & IT, d SG & A,
e IGI & A
26 J. Butler et al.
123
5 Discussion
As expected, when all hallmarks are available for activa-
tion the tumour grows to the largest extent, presumably as
these tumours can take advantage of all hallmarks and the
different abilities each confers. It was also expected that
knocking out 2 hallmarks would significantly lower the
growth of cancer. We hypothesized that certain pairs would
perform better than others, and that knocking out hallmarks
in pairs could have more than just an additive effect.
Half of all tumours with SELF GROWTH knocked out did
not result in a tumour. SG allows a tumour to extend
beyond the normal boundary of growth. In areas of the
body where growth factor is limited, this would be a very
important hallmark. However if a tumour is growing where
there is ample growth factor the hallmark may be less
effective as a drug target.
All simulations with ANGIOGENESIS knocked out failed to
result in a tumour. Similar to SG, ANGIOGENESIS allows a cell
to live outside the predefined blood boundary. One reason
the ANGIOGENESIS hallmark is more powerful is because it
conveys benefit to not just the cell with the mutation, but
surrounding cells, as all nearby cells benefit from the new
vasculature.
The last hallmark that was knocked out in more than one
pair that did not lead to a tumour is GENOME INSTABILITY.
Since GENOME INSTABILITY can lead to all of the other
mutations being activated more frequently this is
understandable.
As evident in Fig. 3, there is a bifurcation in total cell
count—either similar to both hallmarks or almost none.
This is because cell populations which result in a tumour
show almost exponential growth and are not limited by
oxygen or space due to acquired mutations. Cell popula-
tions that do not result in a tumour are limited by both of
these factors, and so eventually almost all cells die as this
overpopulation cannot be sustained by the normal
vasculature.
It is interesting that of the phenotypes that dominated
clones at the end of simulation (shown in Fig. 4), many
cells with a single mutation grew quickly but died off.
Single mutation phenotypes were largely present, but in
dead cells. In contrast, the phenotypes that dominated and
were still alive had multiple mutations. While multiple
mutations increase the chances of death by the immune
system and apoptosis, this suggests it still conveys a very
strong advantage overall. This supports the hypothesis that
knocking out multiple hallmarks, if you can find the correct
pairs, will be better than single target treatments.
Many knockouts did not prevent the tumour from
forming. For example, all knockouts that included IGNORING
GROWTH INHIBITION still resulted in a tumour, except for one
(IGI & A). In our model IGI allows cells to grow even
when there is no space around them, but this only conveys
an advantage to internal cells. Cells on the proliferating
edge always have space, and therefore removing it does not
seem to hurt growth to a significant degree. This could be a
limitation of the model as in reality the proliferating rim of
a tumour may have space constraints from surrounding
tissue.
Other limitations of the model include the fact that AN-
GIOGENESIS only provides a benefit to itself or cells imme-
diately around it. In addition, it only provides an advantage
while the cell is living. In reality angiogenic cells start the
creation of blood vessels and those remain even if the cells
die.
Fig. 3 Total alive cancer cell count every 400 simulation steps is
shown. Each hallmark-knockout pair was simulated and run 10 times.
The average cell count from these runs was calculated and plotted
Fig. 4 Each tumour at the end of the simulation had different
phenotypes present. The top 10 phenotypes, by total number in the
tumour, in each separate simulation were recorded at the end of
simulation and totals were plotted
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6 Conclusions
We have modelled the impact of cancer hallmarks, as
proposed by Hanahan and Weinberg, on early tumour
growth using a cellular automaton model of cancer cells
and lattice Boltzmann methods for two phase fluids (oxy-
gen in the blood, which is more physiologically relevant
than the more common choice of modelling just oxygen or
blood alone, as oxygen is a fluid transported in blood)
(Hanahan and Weinberg 2000, 2011). Our results show that
knocking out pairs of hallmarks does not necessarily have
an additive effect. Santos et al. found that AVOIDING APOP-
TOSIS and IGNORING GROWTH INHIBITION were the most critical
hallmarks independently when cells had a high rate of
mutation, and they also found that IGNORING TELOMERES and
SELF GROWTH had a small impact (Santos and Monteagudo
2012). Looking at the impact of knocking out both AVOID-
ING APOPTOSIS and (IGNORING GROWTH INHIBITION), we did not
see a significant decrease in tumour growth. This is inter-
esting as it is not what would be expected from the findings
of knocking out singular hallmarks if one assumes linear
combination of knockout effects.
We found that knocking out the ability for a cancer cell
to SELF GROW and AVOID IMMUNE SYSTEM, as well as SELF
GROW and be GENETICALLY UNSTABLE, prevent a tumour from
growing. Neither SELF GROWTH nor GENETIC INSTABILITY had a
great effect in the simulations done by Santos et al. (the
immune system was not modelled in this work) however in
combination they had a strong and significant effect. This
supports our hypothesis that knowing the impact of indi-
vidual hallmarks, which can be extended to individual
drugs, does not necessarily give insight into the impact of
combining those knockouts and drugs.
Lastly, we found that knocking out the ability for cells to
INDUCE ANGIOGENESIS combined with any other hallmark
prevented tumour growth. Research has been done into
anti-angiogenesis drugs however the conclusions were not
always positive. Patients still died from small tumours
throughout the body as opposed to one large tumour, which
was seen without the drugs (Ebos et al. 2009). It is
Table 2 Phenotype codes and
the corresponding hallmarks
present in the phenotype
Code Hallmarks present
0 Healthy
128 Healthy dead
4 Angiogenesis
132 Dead, angiogenesis
192 Dead, self groth
144 Dead, avoids apoptosis
169 Dead, ignores growth inhibition, ignores telomers, avoids immunity
29 Avoids immunity, angiogenesis, ignores telomere, avoids apoptosis
136 Dead, ignore telomeres
139 Dead, avoids immunity, genome unstable, ignores telomere
22 Genome unstable, angiogenesis, avoids apoptosis
68 Angiogenesis, self grows
36 Angiogenesis, ignores growth inhibition
64 Self growth
16 Avoids apoptosis
8 Ignores telomeres
2 Genome unstable
86 Genome unstable, angiogenesis, avoids apoptosis, self growth
82 Genome unstable, avoid apoptosis, self growth
196 Dead, angiogenesis, self grows, dead
134 Dead, genome unstable, angiogenesis
54 Genome unstable, angiogenesis, avoids apoptosis, ignores growth inhibition
52 Angiogenesis, avoids apoptosis, ignores growth inhibition
178 Dead, genome unstable, avoids apoptosis, ignores growth inhibition
6 Genome unstable, angiogenesis
164 Dead, angiogenesis, ignores growth inhibition
32 Ignores growth inhibition
28 Angiogenesis, ignores telomere, avoids apoptosis
12 Angiogenesis, ignores telomere
28 J. Butler et al.
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hypothesized that without angiogenesis, other factors
became important, such as metastasis. Perhaps the key is
preventing cells from inducing angiogenesis and limiting
other cancerous abilities. Currently trials are underway to
test pairing anti-angiogenesis drugs with various
chemotherapy drugs for multiple types of cancer including
breast, colon and medulloblastoma (Chinese Academy of
Medical Sciences 2014; International breast cancer study
group 2014; Hoffmann-La 2014; Medical University of
Vienna 2014; Hellenic Oncology Research Group 2014)—
in other words, combination therapy trials.
We have found that the effect of knocking out cancer
hallmarks in pairs can have varying levels of success. This
suggests that clinical research should be done into combi-
nation drug treatment as not all drugs that are strong
individually will necessarily be strong in combination.
Since cancer treatments can be physically and emotionally
challenging for patients, knowing in advance what com-
binations will not be successful could greatly enhance the
quality of life of people undergoing cancer treatment.
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